Key result
Immune cells undergo mesenchymal reprogramming to produce matrix and drive fibrotic remodeling.
Why the study?
Emerging evidence challenges the traditional view that fibrosis is solely fibroblast-centred, indicating immune cells can acquire mesenchymal-like functions contributing directly to tissue remodelling.
Recognizing immune-cell fibrotic plasticity expands the traditional myofibroblast-centered paradigm of fibrosis and may inform the development of more selective antifibrotic therapies.
May identify novel antifibrotic targets via immune cell plasticity; hypothesis-generating and requires prospective validation before clinical adoption.
Fibrosis has traditionally been viewed as a fibroblast- and myofibroblast-centred process, in which immune cells regulate matrix deposition primarily through inflammatory mediators and paracrine signalling. However, advances in single-cell profiling, spatial analyses and lineage-resolved approaches are beginning to challenge this rigid division of cellular labour. Emerging evidence indicates that, in persistently injured and maladaptively repairing tissues, selected immune cell populations can acquire matrix producing, cytoskeletal remodelling and mesenchymal-like functions, thereby contributing more directly to structural tissue remodelling. In this Review, we introduce the concept of immune cell fibrotic plasticity and critically assess the evidence, regulatory mechanisms and pathological significance of fibrotic effector states in macrophages, neutrophils and T cells. Macrophage reprogramming towards myofibroblast-like states appears to be shaped by convergent TGF-β/SMAD signalling, metabolic adaptation and epigenetic regulation. Neutrophils can synthesize, transport and organize extracellular matrix, conferring temporally distinct functions in tissue stabilization and pathological scarring. Evidence for mesenchymal-like reprogramming of T cells remains limited, but raises the possibility that adaptive immune cells can also acquire structural effector functions. Importantly, co-expression of immune and mesenchymal markers does not, by itself, establish stable lineage conversion. These phenomena are more appropriately understood as microenvironmentally induced, context-dependent functional states rather than universal or complete transdifferentiation. Defining the origins, reversibility and quantitative contribution of these states will determine whether immune-cell fibrotic plasticity can be exploited for disease stratification and the development of more selective antifibrotic therapies.
No takes yet. Share an insight, caveat, or question.
Long et al. (2026) conducted a review in Fibrosis. Selected immune cell populations, including macrophages, neutrophils, and T cells, can undergo mesenchymal-like reprogramming to acquire matrix-producing functions and contribute to fibrotic remodeling.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: